# Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

> **NCT00469209** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Trisenox (Arsenic Trioxide)
- **DRUG:** Velcade (Bortezomib)
- **DRUG:** Melphalan
- **DRUG:** Vitamin C (Ascorbic Acid)

## Key facts

- **NCT ID:** NCT00469209
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469209, "Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00469209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*